Announcement PDF ASX Release 13 February 2025 Cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) in respect of the Director Placement Shares Acrux Ltd (ASX:ACR) (Company) gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act). The Company refers to the Extraordinary General Meeting held on 3 February 2025 at which shareholders approved the issue of fully paid ordinary shares to Directors following their participation in the Share Placement and announces that 3,714,284 fully paid ordinary shares (Director Placement Shares) have today been issued to Directors. The Director Placement Shares were issued on the same terms and conditions as all other shares issued in relation to the Share Placement and Share Purchase Plan announced on 5 December 2024. The Company gives notice that: (1) the Company issued the Director Placement Shares without disclosure to investors under Part 6D.2 of the Act; (2) this notice is being given under section 708A(5)(e) of the Act; (3) as at the date of this notice, it has complied with: (a) the provisions of Chapter 2M of the Act as they apply to the Company; and (b) sections 674 and 674A of the Act; and (4) as at the date of this notice, there is no information that is “excluded information” (as defined in sections 708A(7) and (8) of the Act) which is required to be set out in this notice under section 708A(6)(e) of the Act. This announcement has been authorised for release to the ASX by the Managing Director. For more information, please contact: Michael Kotsanis CEO & Managing Director E: michael.kotsanis@acrux.com.au Joanna Johnson CFO & Company Secretary E: joanna.johnson@acrux.com.au P: + 61 3 8379 0100 About Acrux Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au